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One new lathyrane diterpenoid, Jatropodagrene (1) along with three known compounds have 
been isolated from the root bark of Jatropha podagrica. The structure of the new compound 
was established from its 1D and 2D NMR spectra and in comparison with data reported in 
previous literatures. Compound 1 was highly cytotoxic (98.86% inhibition) to the HCV virus, 
while compounds 2 (EC50, EC90, CC50 5.8, 33.1, 22.6 µg/mL, respectively) and 3 displayed 
significant anti HCV activity. This is the first report of the anti hepatitis C virus activity of 
lathyrane skeleton and J .podagrica.  
  





Hepatitis C is attracting serious attention from scientists 
worldwide with a view to discovering new leads drugs 
for combating it. Hepatitis C virus (HCV) is a positive-
stranded RNA virus, possessing a 9.6 kb genome 
encoding a single polyprotein that is subsequently 
cleaved by both host and virus protease into 10 sub 
units proteins, comprising six nonstructural and four 
structural proteins (Linderbach & Rice, 2005). It has 
been estimated that approximately 175 million people 
worldwide are chronically infected with HCV, and it is 
one of the leading causes of chronic hepatitis, cancer of 
the liver and cirrhosis (Lin et al., 2006). Because the 
virus does not establish latency, it is possible to 
eradicate it (Schinazi et al, 2009; Shepard et al., 2005). 
To date, no vaccine against HCV has been developed 
owing to the presence of large numbers of HCV 
genotypes and quasi species, and lack of easily 
available animal models for vaccination tests (Bobeck 
et al., 2010). Therefore, it is obvious that new and 
better drugs obtained from natural sources are required 
in the battle against HCV.  Jatropha podagrica Hook 
(JP) is used in parasitic skin infections, hepatitis, cancer 
related diseases (Aiyelaagbe et al., 2007). The paper 
reports the isolation of one new, two known 
diterpenoids and one flavonoid from JP and their HCV 
activity.  
 
MATERIALS AND METHODS 
 
General 
The 1H and 13C NMR spectra were recorded in CDCl3-
d6  at 400 MHz. The HRESIMS data were obtained 
using an Agilent MS TOF 1100 Series with 
electrospray ionization. The optical rotation was 
measured with a JASCO DIP 370 digital polarimeter. 
The 1H and 13C NMR spectra were recorded in CDCl3-
d6 (δH 7.25/δC 72.36) using a Brucker NMR 
spectrometer operating at 400 MHz for 1H and 13C 
nuclei. The NOESY spectrum was recorded at 25°C 
using a NOE pulse sequence with a mixing time of 500 
Diterpenoids, Jatropha  podagrica and Hepatitis C virus 
 
22  J. Afr. Ass. Physiol. Sci. 2 (1): 2014      Falodun et al 
 
ms, and the experiment was performed for 24 h with 
the concentration of the sample at 6 mg/mL. The 
HRESIMS data were obtained using an Agilent MS 
TOF 1100 Series with electrospray ionization. HPLC 
was carried out using a Waters 486 Series with a 
Phenomenex C18 column (10.0 × 250 mm) and an 
1100 Series multiple wavelength detector. 
 
Plant material and extraction 
Plant material was collected from Edo State, Nigeria 
between January and June, 2013, identified and 
authenticated by Mr. Ugbogu O. A. and Shasanya O. S. 
of the Forest Research Institute of Nigeria (FRIN), 
where a voucher specimen (FHI 93265) was deposited 
in the herbarium. The shade dried plant material (400 
g) was powdered and extracted with 1 liter methanol 
for 48 hr (3 X) by cold maceration. The MeOH extract 
(50g) was fractionated by VLC using a gradient system 
with hexane-EtOAc (100:0, 50:50, 0:100) and EtOAc-
MeOH (50:50, 0:100). The hexane: ethylacetate (50%) 
fraction was further purified with LH-20 sephadex 
eluted with DCM:MeOH (1:1) to afford fractions I-VII. 
Two fractions that displayed anti HCV activity were 
purified by semi-preparative reversed-phase HPLC 
(diameter, 10 mm x length, 250 mm, 10 µm) eluted 
with CH3CN/H2O (70-100%) yielded 1 (tR 13.8 min, 5 
mg), 2 (tR 6.0 min, 4.5 mg) and 3 ( tR 16.0 min, 6 mg). 
Compound 4 was obtained as colorless crystals from 
fraction III. Compound 1: Light yellow solid: mp; 178-
179oC, [α]25D-130o (CHCl3; c0.001); UV (MeOH) λmax 
nm (log e) 252; 1H and 13C-NMR data, see Table 1; 
HREIMS ([M]+, m/z 330.1831, calcd.for C20H26O4). 
Compound (2): Yellow oil; [α]25D-175o,: (c0:001, 
CHCl3); UV (MeOH) λmax nm (255; 1H and 13C-NMR 
data m/z (rel. int.): 332 [M]+ (1), 314 [M  H2O]+ (1), 
299 (2), 271 (6), 161 (7), 95 (16), 81 (16) 55 (32) 43 
(100) (Aiyelaagbe et al., 2007). Compound (3): White 
solid; mp 54-55oC; [α]25D-175o, (c0:0026,  CHCl3;); UV 
(MeOH) λmax nm 265. 1H and 13C-NMR data 
(Aiyelaagbe et al., 2007). EIMS (probe) 70 eV m/z (rel. 
int.): 314 [M  H2O]+ (2), 299 (2), 271 (11), 161 (34), 
109 (26). Compound (4): Colorless crystals, mp 178-
180oC. UV (MeOH) λmax nm: 215.0, 255.0, 308.5. EI-
MS m/z (rel. int.): 222 [M+, 100], 207 (39), 189 (5), 179 
(12), 161 (14), 151 (14), 133 (11) (Ee et al., 2005).  
 
Anti HCV assay 
Antiviral and Cytotoxicity assays for HCV: Cells were 
maintained in Dulbecco’s modified Eagles medium 
high glucose 4.5 g/L supplemented with 10% fetal 
bovine serum, 1% L-glutamine, 1% penicillin and 
streptomycin, 1% L-pyruvate and 500 µg/mL of 
genticin (G418; Invitrogen). Genticin was used to 
select cells permitting the HCV RNA replication. The 
antiHCV activity was done using the method of 
Schinazi et al., (2010). 
Cell Culture 
Cells were seeded in 6-well plates at a density of 2.5 x 
105 cells per well, 16 h before the beginning of 
treatment. Cells were treated with the molecules 
administered at different concentrations in complete 
medium that did not contain genticin. Administration of 
each compound was renewed every day for three 
consecutive days. Ribavirin (ICN Pharmaceuticals), 
mycophenolic acid (Sigma) and IFNa-2b (IntronA) 
were used in the same conditions as positive controls. 
Total RNA was extracted at the end of treatment (24 h 
after the last day of treatment) with the reagent 
(Eurobio), which is a mix of phenol and guanidinium 
thiocyanate. Northern blot analysis was then performed 
using 6022 V NorthernMaxTM-Gly kit (Ambion), 
following manufacturer’s instructions. Five micrograms 
of total RNA were desaturate in global buffer at 5oC for 
30 min,  separated by 1.1% agarose gel electrophoresis 
and then transferred for 12 hr onto a charged nylon 
membrane (Hybond+, Marshal). Hybridization was 
carried out with three different [32P]CTP- labelled 
riboprobes obtained by in vitro transcription 
(Riboprobe in vitro transcription system; Promega). 
Two probes were complementary to the NS5A region 
of the HCV genome of negative polarity and positive 
polarity. A third probe was complementary to the beta-
actin mRNA and obtained by in vitro transcription from 
a specific plasmid (pTRI beta actin human, reference 
7424; Ambion). First, the blot was hybridized with the 
riboprobes directed against the negative strand of HCV 
RNA and beta-actin mRNA. After one night of 
hybridization at 68oC, the membrane was washed, and 
then exposed to X-ray film and a phosphor screen 
(phosphorimager). This screen was then scanned and 
quantitative analysis was achieved using ImageQuant 
software. The amount of beta-actin mRNA was used as 
an internal loading control to standardize the amount of 
HCV RNA detected. The same membrane was 
subsequently hybridized with the negative sense 
riboprobe to determine the level of positive strand HCV 
RNA, using the same approach. For cell viability 
assays, cells were seeded in 96-well plates at a density 
of 12,500 cells per well. They were treated by the 
different extracts with the same concentration 
conditions as those used for the antiviral assays. Then, 
cell viability was measured by neutral red assay. 
Neutral red which specifically colours lysosomes and 
its accumulation depends on cellular membrane 
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integrity. The yield of neutral red incorporated in cells 
is proportional to the number of living cells. At the end 
of treatment, culture medium was removed; cells were 
washed by PBS and then coloured with neutral red at 
0.005% for 3 hr at 37oC. Cells were then fixed 1 min by 
formol calcium and lysed by a treatment with a v/v 
mixture of acetic acid and ethanol. After 15 min 






Compound 1 was obtained as a white solid; its 
molecular formula C20H26O4 was established from its 
mass spectrum HREIMS ([M]+, m/z 330.1830).The 
structure was unambiguously resolved from the 
analysis of its 1D and 2D NMR (HMQC) and (HMBC) 
spectral. Spectral obtained were compared with 
reported data in literature. The IR spectrum showed the 
presence of diagnostic carbonyl groups at 1730, 1710 










































 The 1H-NMR spectral data (Table 1) revealed the 
presence of a cycloprapane moiety, one oleifinic proton 
(δ 6.90) and five methyl groups. On the other hand, the 
13C-NMR spectral data (Table 1) showed the presence 
of two double bonds in ring A, two carbonyl groups, 









 Table 1: 1H- and 13C-NMR (CDCI3) spectral data of 
compound 1    
 





1 135.6  CH 6.90 (1H, s) C-1, 2, 3, 15 
2 167.2 C -  
3 207.5 C=O -  
4 166.3  C -  
5 60.3 CH 3.07 (1H, d, 
J =8.5Hz) 
C-3, 4, 5 
6 56.2 C   
7 36.3 CH 1.10 m  C-6, 7, 8, 9 
8 40.5 CH2 1.80 m  C-7, 8, 9 
9 28.7 CH 0.19 m  C-8, 9, 10 
10 17.7 C   
11 18.0 CH 0.57 m  C-10, 11, 12 
12 40.3 CH2 1.81 m  C-11, 12, 13 
13 43.4 CH 3.24 m C-12, 13, 14 
14 208.2 C=O   
15 135.6 C   
16 18.5 CH3 1.85 (3H, d, 
J= 5.6 Hz) 
C-1, 2, 3 
17 23.4 CH3 1.41 s C-6, 7 
18 28.2 CH3 0.99 s C-9, 10, 19 
19 15.5 CH3 0.77 s C-10, 11, 18 
20 
OH 
15.0 CH3 1.16 (3H, d, 
J = 6.0Hz)  
3.88, s 
C-12, 13, 14 
 
 
The 13C-NMR showed the presence of two keto groups 
(δ 207.5 and δ 208.2) and epoxide group (δ 60.3.7 and 
δ 56.2).  The downshift carbonyl group was consistent 
with the cyclopentanone chemical nucleus. The spectra 
data of Compounds 2-4 were compared with literature. 
As shown in Table 2, these compounds generally 
exhibited good inhibition of HCV of 98.86%, 89.71% 
and 82.61 % for 1, 2 and 3 respectively, except 
compound 4 which had only low activity 17.02 and 
7.49% for HCV and rRNA respectively). The most 
potent compound was 1 with pronounced cytotoxicity. 
It is noteworthy that compound 2 showed potent 
antiviral activity (EC50 , EC90, CC50 of 5.8, 33.1 and 22.6 
respectively (Table 3).  Compound 4 did not display 
potent activity indicating that the lathyrane nucleus, 
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Table 2: Anti HCV activities of compounds (1-4) 
Treatment Concentration 
(µg/mL) 
DCt HCV  DCt  
rRNA 
% inhibition 
  HCV    rRNA 
      
1 10 6.49 UND 98.86 UND 
2  10 3.29 1.34 89.71 60.29 
3  10 2.53 1.14 82.61 54.47 
4 10 0.25 0.11 17.02 7.49 
UND; not determined 
 
 







 % inhibition 
 
 EC values(µg/mL) 
     HCV rRNA  aEC50 bEC90 cCC50 
           
2 33 3.31 1.21  89.86 56.71  5.8 33.1 22.6 
 10 1.37 0.79  61.20 41.93     
 3 0.80 0.33  42.33 20.21      
 1 0.38 0.02  22.92 1.37     
3 33 0.55 0.06  31.46 4.28  ND ND ND 
 10 -0.73 -0.31  65.60 -24.17     
 3 -0.10 -0.45  -7.15 -36.79     
 1 0.09 -0.13  6.03 -9.65     
ND, not Determined. 
aEC50: The concentration that affords 50% inhibition of viral growth. 
bEC90: The concentration that affords 90% inhibition of viral growth 






Compound 1 was isolated from Jatropha podagrica 
(400 g). A methanol extract of the root bark of J. 
podagrica was subjected to silica gel vacuum-liquid 
chromatography (VLC) followed by fractionation on an 
LH-20 Sephadex CC eluted with DCM:MeOH (1:1). 
Then purification steps used C18 column and 
semipreparative HPLC (Phenomenex C18 column 10.0 
× 250 mm) at a flow rate of 3 mL/min to yield 1. A 
comparison of these spectral data of 1 with those of the 
known constituents of Jatropha species suggested that 
the structure of 1 is closely related to that of 2 
(Schmeda-Hirschmann et al., 1992). However, the 
double bond in ring A appeared in positions C-1, C-2 
and C-4, C-15 in 1. The presence of a 1,1-
dimethylcyclopropane ring was evident from the 
corresponding 1H and 13C- NMR chemical shifts and 
from NMR comparisons with similar compounds. The 
chemical shift of the 1HNMR in Table 1 shows the 
presence of one olefinic proton at the β-position of one 
of the keto groups. The 2D NMR indicated the 
presence of cyclopropane moiety (H-9 and H-11 with 
gem-dimethyl at C-10 position). The HMBC 
experiment (Table 1) showed the long range coupling 
between the protons and carbons. The C-4–C-15 double 
bond was assigned based on comparison of the NMR 
data with similar compounds in the literature 
(Schmeda-Hirschmann et al., 1992). Structure 1 was 
thus named japodagrene. The structure represents the 
lathyrane ring system which is common in the 
Euphorbiaceae family, but 1 is the first compound to 
have two double bonds on the cyclopentanone ring. 
Compounds 2-4 have previously been isolated 
(Aiyelaagbe et al., 2007; EEe et al., 2005). The 
potential anti-HCV activity of the isolated lathyrane 
diterpenoids, together with that of the fraxadin (4) were 
evaluated (Tables 2-3). The cytotoxicity of each 
compound was expressed as the concentration of 
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compound required to kill 50% (CC50) of the DCt HCV 
cells. 
In summary, Compounds 1-3 proved to be potential 
HCV inhibitors, with 1 as the most potent. Such 
activity profiles make them attractive candidate 
compounds for in vivo studies. 
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